Literature DB >> 23757117

Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study.

P W S Rosario1, J B N dos Santos, M R Calsolari.   

Abstract

The importance of thyroglobulin (Tg) stimulation after ablation in patients with papillary thyroid carcinoma (PTC) and undetectable basal Tg measured with sensitive assays has been questioned. However, there is a need for prospective studies that evaluate the evolution of these patients when stimulated Tg is omitted and this was the objective of the present investigation. One hundred twenty-two consecutive patients with PTC with the following characteristics were evaluated: submitted to total thyroidectomy and remnant ablation; low risk for recurrence; undetectable basal Tg (functional sensitivity of 0.1 ng/ml) 6 months after initial therapy; anti-Tg antibodies (TgAb) negative, and neck ultrasound (US) showing no abnormalities. These patients were not submitted to Tg stimulation. After follow-up for 24-78 months, only one patient (0.8%) presented apparent disease (lymph node metastases). TgAb were detected at low titers and without progression in 1 patient (0.8%). Tg became detectable and continued to be detectable in 3 patients (2.4%), but at concentrations ≤0.3 ng/ml in the absence of further increases, with stimulated Tg < 1.4 ng/ml. A total of 117 patients (96%) coursed with no apparent disease throughout follow-up and had undetectable Tg at the end of the study. Of these, 111 showed undetectable Tg in all measurements and 6 showed detectable Tg in some of them, although Tg later returned spontaneously to an undetectable range. After ablation, the risk of recurrence is very low in patients with low-risk PTC who show undetectable basal Tg measured with a sensitive assay, negative TgAb and negative US. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23757117     DOI: 10.1055/s-0033-1347264

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Accuracy of unstimulated Basal serum thyroglobulin levels in assessing the completeness of thyroidectomy.

Authors:  Emin Gurleyik; Sami Dogan
Journal:  J Clin Med Res       Date:  2014-07-28

2.  Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Int J Endocrinol       Date:  2015-08-09       Impact factor: 3.257

Review 3.  Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper.

Authors:  Luca Giovanella; Penelope M Clark; Luca Chiovato; Leonidas Duntas; Rossella Elisei; Ulla Feldt-Rasmussen; Laurence Leenhardt; Markus Luster; Camilla Schalin-Jäntti; Matthias Schott; Ettore Seregni; Herald Rimmele; Jan Smit; Frederik A Verburg
Journal:  Eur J Endocrinol       Date:  2014-04-17       Impact factor: 6.664

4.  Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging.

Authors:  Guanghui Liu; Na Li; Xuena Li; Song Chen; Bulin Du; Yaming Li
Journal:  Biomed Res Int       Date:  2016-01-21       Impact factor: 3.411

5.  miR-98-5p promotes apoptosis and inhibits migration and cell growth in papillary thyroid carcinoma through Bax/Caspase-3 by HMGA2.

Authors:  Kai Qiu; QingJi Xie; Shan Jiang; Ting Lin
Journal:  J Clin Lab Anal       Date:  2019-10-31       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.